<DOC>
	<DOCNO>NCT00369304</DOCNO>
	<brief_summary>This open-label , randomize , 2-period crossover , inpatient study perform healthy subject . The study consist 2 treatment period : There 2 parallel cohort 12 subject enrol receive single dos tolbutamide AGG-523 plus tolbutamide period 1 2 crossover design . Doses test article administer overnight fast least 10 hour .</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetics Potential Drug Interaction Between CYP2C9 Inhibitor Substrate</brief_title>
	<detailed_description />
	<mesh_term>Cytochrome P-450 CYP2C9 Inhibitors</mesh_term>
	<criteria>1 . Men woman , age 18 50 year . Women nonchildbearing potential may include . 2 . Body mass index range 18 30 kg/meter square body weight equal great 50 kg . 3 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12 lead electrocardiogram ( graphic trace pattern heart beat ) . 4 . Nonsmoker smoker few 10 cigarette ( half pack ) per day determine history . Must abstain smoke inpatient stay . 5 . Have high probability compliance completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Health</keyword>
</DOC>